Clinical use

The thiazolidinediones are approved for use as monotherapy or in combination with secretagogues, metformin, or insulin therapy. Unlike most antidiabetic medications, which have a rapid onset of activity, pioglitazone and rosiglitazone require 8-12 weeks or more to achieve maximal clinical benefit. This is probably related to their mode of action, i.e., the regulation of gene expression. To date, there have been no head-to-head studies comparing rosiglitazone and pioglitazone, and no studies on patient characteristics that may predict a good treatment response with these agents.

When used as monotherapy or adjunctive therapy, thiazolidinediones typically decrease HbA1C by 1-1.5%.70 Clinical studies with rosiglitazone monotherapy lowered FPG by up to 55mgdL_ 1. Similarly, pioglitazone (15, 30, and 45 mg doses) reduced FPG (by 30, 32, and 56mgdL_ 1, respectively) and HbA1C (by 0.3, 0.3, and 0.9%, respectively).71 Dividing the daily dose (twice daily) was more effective in reducing both FPG levels and HbA1C levels compared with single daily dosing.72

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook

Post a comment